Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock
- PMID: 3175328
Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock
Abstract
Defibrotide stimulates PGI2 production and exerts significant antithrombotic, fibrinolytic and plasminogen-activating activities. We studied its effects in splanchnic artery occlusion (SAO) shock in rats. Anesthetized rats subjected to total occlusion of the celiac and superior mesenteric arteries for 40 minutes developed a severe shock state following reperfusion usually resulting in death 90-120 minutes after releasing the clamps. Defibrotide 910 mg/kg +25 mg/kg/h) treated SAO shock rats maintained higher post-reperfusion mean arterial blood pressure compared to those receiving only the vehicle (0.9% NaCl). SAO shock rats treated with defibrotide exhibited lower plasma activities of the lysosomal protease cathepsin D (p less than 0.05 from vehicle) and myocardial depressant factor (p less than 0.02 from vehicle) as well as the plasma accumulation of free amino-nitrogen compounds (p less than 0.05 from vehicle). All SAO shock rats treated with defibrotide survived the entire 120 post-release period compared with only a 42% survival rate for rats receiving only the vehicle (p less than 0.02). These results suggest a remarkable protective effect of defibrotide in SAO shock.
Similar articles
-
Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.Methods Find Exp Clin Pharmacol. 1988 Jul;10(7):413-8. Methods Find Exp Clin Pharmacol. 1988. PMID: 3419244
-
Effects of prostacyclin and taprostene in splanchnic artery occlusion shock.Eicosanoids. 1991;4(1):15-20. Eicosanoids. 1991. PMID: 2059456
-
Novel beneficial mechanisms of defibrotide, a prostacyclin enhancing agent in splanchnic artery occlusion and reperfusion in rats.Methods Find Exp Clin Pharmacol. 1991 Dec;13(10):667-74. Methods Find Exp Clin Pharmacol. 1991. PMID: 1663194
-
An integrated view of the activities of defibrotide.Semin Thromb Hemost. 1996;22 Suppl 1:71-5. Semin Thromb Hemost. 1996. PMID: 8807733 Review.
-
Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1-2):177-80. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988. PMID: 2459016 Review.
Cited by
-
Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.Drugs. 1993 Feb;45(2):259-94. doi: 10.2165/00003495-199345020-00007. Drugs. 1993. PMID: 7681375 Review.
-
Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion.Naunyn Schmiedebergs Arch Pharmacol. 1990 Mar;341(3):246-50. doi: 10.1007/BF00169738. Naunyn Schmiedebergs Arch Pharmacol. 1990. PMID: 2160617
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical